Delaware’s highest state court has confirmed that healthcare company Fresenius was entitled to pull out of its multibillion-dollar acquisition of Akorn after finding that the generic drugmaker had misrepresented the state of its data.
Delaware Supreme Court upholds Fresenius/Akorn decision
Updated as of: 10 December 2018
